{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T15:45:33Z","timestamp":1794411933236,"version":"4.9.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2013,5,18]],"date-time":"2013-05-18T00:00:00Z","timestamp":1368835200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drugs Aging"],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1007\/s40266-013-0090-z","type":"journal-article","created":{"date-parts":[[2013,5,17]],"date-time":"2013-05-17T06:59:37Z","timestamp":1368773977000},"page":"587-592","source":"Crossref","is-referenced-by-count":92,"title":["Dopamine Agonist Withdrawal Syndrome: Implications for Patient Care"],"prefix":"10.1007","volume":"30","author":[{"given":"Melissa J.","family":"Nirenberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,5,18]]},"reference":[{"key":"90_CR1","first-page":"CD006564","volume":"2","author":"RL Stowe","year":"2008","unstructured":"Stowe RL, Ives NJ, Clarke C, van Hilten J, Ferreira J, Hawker RJ, et al. Dopamine agonist therapy in early Parkinson\u2019s disease. Cochrane Database Syst Rev. 2008;2:CD006564.","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"90_CR2","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1159\/000341996","volume":"11","author":"D Weintraub","year":"2013","unstructured":"Weintraub D, Nirenberg MJ. Impulse control and related disorders in Parkinson\u2019s disease. Neurodegener Dis. 2013;11(2):63\u201371.","journal-title":"Neurodegener Dis"},{"issue":"4","key":"90_CR3","doi-asserted-by":"crossref","first-page":"295","DOI":"10.2165\/11318330-000000000-00000","volume":"27","author":"LD Wood","year":"2010","unstructured":"Wood LD. Clinical review and treatment of select adverse effects of dopamine receptor agonists in Parkinson\u2019s disease. Drugs Aging. 2010;27(4):295\u2013310.","journal-title":"Drugs Aging"},{"issue":"5","key":"90_CR4","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1001\/archneurol.2010.65","volume":"67","author":"D Weintraub","year":"2010","unstructured":"Weintraub D, Koester J, Potenza MN, Siderowf AD, Stacy M, Voon V, et al. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol. 2010;67(5):589\u201395.","journal-title":"Arch Neurol"},{"issue":"3","key":"90_CR5","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s10899-009-9123-2","volume":"25","author":"AJ Holman","year":"2009","unstructured":"Holman AJ. Impulse control disorder behaviors associated with pramipexole used to treat fibromyalgia. J Gambl Stud. 2009;25(3):425\u201331.","journal-title":"J Gambl Stud"},{"issue":"5","key":"90_CR6","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/WNF.0b013e3182281b2f","volume":"34","author":"J Martinkova","year":"2011","unstructured":"Martinkova J, Trejbalova L, Sasikova M, Benetin J, Valkovic P. Impulse control disorders associated with dopaminergic medication in patients with pituitary adenomas. Clin Neuropharmacol. 2011;34(5):179\u201381.","journal-title":"Clin Neuropharmacol"},{"key":"90_CR7","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/1471-2377-11-117","volume":"11","author":"V Voon","year":"2011","unstructured":"Voon V, Schoerling A, Wenzel S, Ekanayake V, Reiff J, Trenkwalder C, et al. Frequency of impulse control behaviours associated with dopaminergic therapy in restless legs syndrome. BMC Neurol. 2011;11:117.","journal-title":"BMC Neurol"},{"issue":"5","key":"90_CR8","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1097\/wnf.0b013e31804c780e","volume":"30","author":"ED Driver-Dunckley","year":"2007","unstructured":"Driver-Dunckley ED, Noble BN, Hentz JG, Evidente VG, Caviness JN, Parish J, et al. Gambling and increased sexual desire with dopaminergic medications in restless legs syndrome. Clin Neuropharmacol. 2007;30(5):249\u201355.","journal-title":"Clin Neuropharmacol"},{"issue":"4","key":"90_CR9","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1002\/mds.20757","volume":"21","author":"MJ Nirenberg","year":"2006","unstructured":"Nirenberg MJ, Waters C. Compulsive eating and weight gain related to dopamine agonist use. Mov Disord. 2006;21(4):524\u20139.","journal-title":"Mov Disord"},{"issue":"3","key":"90_CR10","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1212\/01.WNL.0000076478.45005.EC","volume":"61","author":"E Driver-Dunckley","year":"2003","unstructured":"Driver-Dunckley E, Samanta J, Stacy M. Pathological gambling associated with dopamine agonist therapy in Parkinson\u2019s disease. Neurology. 2003;61(3):422\u20133.","journal-title":"Neurology"},{"issue":"1","key":"90_CR11","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1001\/archneurol.2009.294","volume":"67","author":"CA Rabinak","year":"2010","unstructured":"Rabinak CA, Nirenberg MJ. Dopamine agonist withdrawal syndrome in Parkinson disease. Arch Neurol. 2010;67(1):58\u201363.","journal-title":"Arch Neurol"},{"key":"90_CR12","unstructured":"Sadock BJ, Kaplan HI, Sadock VA. Kaplan and Sadock\u2019s Synopsis of Psychiatry: Behavioral Sciences\/Clinical Psychiatry. 10th ed. Philadelphia: Wolter Kluwer\/Lippincott Williams & Wilkins; 2007."},{"issue":"2","key":"90_CR13","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1136\/jnnp-2012-302684","volume":"84","author":"M Pondal","year":"2013","unstructured":"Pondal M, Marras C, Miyasaki J, Moro E, Armstrong MJ, Strafella AP, et al. Clinical features of dopamine agonist withdrawal syndrome in a movement disorders clinic. J Neurol Neurosurg Psychiatry. 2013;84(2):130\u20135.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"90_CR14","doi-asserted-by":"crossref","unstructured":"Bastiaens J, Dorfman BJ, Christos PJ, Nirenberg MJ. Prospective cohort study of impulse control disorders in Parkinson\u2019s disease. Mov Disord. 2013;28(3):327\u201333.","DOI":"10.1002\/mds.25291"},{"issue":"3","key":"90_CR15","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3109\/00207454.2011.633722","volume":"122","author":"N Limotai","year":"2012","unstructured":"Limotai N, Oyama G, Go C, Bernal O, Ong T, Moum SJ, et al. Addiction-like manifestations and Parkinson\u2019s disease: a large single center 9-year experience. Int J Neurosci. 2012;122(3):145\u201353.","journal-title":"Int J Neurosci"},{"key":"90_CR16","doi-asserted-by":"crossref","unstructured":"Nirenberg MJ. Dopamine agonist withdrawal syndrome and non-motor symptoms after Parkinson\u2019s disease surgery. Brain. 2010;133(11):e155. author reply e6.","DOI":"10.1093\/brain\/awq165"},{"issue":"9","key":"90_CR17","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.parkreldis.2012.05.012","volume":"18","author":"AL Cunnington","year":"2012","unstructured":"Cunnington AL, White L, Hood K. Identification of possible risk factors for the development of dopamine agonist withdrawal syndrome in Parkinson\u2019s disease. Parkinsonism Relat Disord. 2012;18(9):1051\u20132.","journal-title":"Parkinsonism Relat Disord"},{"issue":"2","key":"90_CR18","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.parkreldis.2012.06.006","volume":"19","author":"BJ Dorfman","year":"2013","unstructured":"Dorfman BJ, Nirenberg MJ. Dopamine agonist withdrawal syndrome in a patient with restless legs syndrome. Parkinsonism Relat Disord. 2013;19(2):269\u201370.","journal-title":"Parkinsonism Relat Disord"},{"issue":"4","key":"90_CR19","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.parkreldis.2011.12.007","volume":"18","author":"JG Hou","year":"2012","unstructured":"Hou JG, Wu LJ, Moore S, Ward C, York M, Atassi F, et al. Assessment of appropriate medication administration for hospitalized patients with Parkinson\u2019s disease. Parkinsonism Relat Disord. 2012;18(4):377\u201381.","journal-title":"Parkinsonism Relat Disord"},{"issue":"2","key":"90_CR20","doi-asserted-by":"crossref","first-page":"157","DOI":"10.4997\/JRCPE.2012.215","volume":"42","author":"MJ MacMahon","year":"2012","unstructured":"MacMahon MJ, MacMahon DG. Management of Parkinson\u2019s disease in the acute hospital environment. J R Coll Physicians Edinb. 2012;42(2):157\u201362.","journal-title":"J R Coll Physicians Edinb"},{"issue":"7","key":"90_CR21","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1358\/dot.2010.46.7.1463530","volume":"46","author":"B Boroojerdi","year":"2010","unstructured":"Boroojerdi B, Wolff HM, Braun M, Scheller DK. Rotigotine transdermal patch for the treatment of Parkinson\u2019s disease and restless legs syndrome. Drugs Today (Barc). 2010;46(7):483\u2013505.","journal-title":"Drugs Today (Barc)"},{"issue":"12","key":"90_CR22","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1212\/01.wnl.0000234880.51322.16","volume":"66","author":"M Schupbach","year":"2006","unstructured":"Schupbach M, Gargiulo M, Welter ML, Mallet L, Behar C, Houeto JL, et al. Neurosurgery in Parkinson disease: a distressed mind in a repaired body? Neurology. 2006;66(12):1811\u20136.","journal-title":"Neurology"},{"issue":"7","key":"90_CR23","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1136\/medethics-2011-100044","volume":"38","author":"F Gilbert","year":"2012","unstructured":"Gilbert F. The burden of normality: from \u2018chronically ill\u2019 to \u2018symptom free\u2019. New ethical challenges for deep brain stimulation postoperative treatment. J Med Ethics. 2012;38(7):408\u201312.","journal-title":"J Med Ethics"}],"container-title":["Drugs & Aging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-013-0090-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40266-013-0090-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-013-0090-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,13]],"date-time":"2019-07-13T18:36:58Z","timestamp":1563043018000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40266-013-0090-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5,18]]},"references-count":23,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["90"],"URL":"https:\/\/doi.org\/10.1007\/s40266-013-0090-z","relation":{},"ISSN":["1170-229X","1179-1969"],"issn-type":[{"value":"1170-229X","type":"print"},{"value":"1179-1969","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,5,18]]}}}